A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06384261
- Locations
- 🇺🇸
University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando, Florida, United States
🇺🇸The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04241549
- Locations
- 🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
🇯🇵Osaka City General Hospital, Osaka, Japan
🇯🇵University of Fukui Hospital, Yoshida, Japan
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04150887
- Locations
- 🇵🇱
Szpital Uniwersytecki w Krakowie, Krakow, Poland
🇨ðŸ‡Kantonsspital St.Gallen, St. Gallen, Switzerland
🇵🇱Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04023526
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇷🇺Oncologic Dispensary No.2, Sochi, Russian Federation
🇷🇺Komi Republic Oncology dispensary, Syktyvkar, Russian Federation
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- Drug: AZA
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03030612
A Study of ARGX-110 in Participants With Advanced Malignancies
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT01813539